Novo Nordisk (NVO.N): etovopivat met both co-primary endpoints in the Phase III HIBISCUS trial for sickle cell disease, significantly reducing vascular occlusive crisis events and improving hemoglobin response in patients with sickle cell disease. In the Phase III trial, etovopivat reduced vascular occlusive crisis events by 27%. The company plans to submit its first regulatory application for etovopivat in the second half of 2026.
